Cancer Genetics, inc. Omnibus Warrant AmendmentOmnibus Warrant Amendment • July 5th, 2018 • Cancer Genetics, Inc • Services-medical laboratories
This Omnibus Warrant Amendment (this “Amendment”) is entered into as of June 30, 2018 (the “Effective Date”), by and among Cancer Genetics, Inc., a Delaware corporation (the “Company”), as issuer, and each of Partners for Growth IV, L.P., a Delaware limited partnership (“PFG”), PFG Equity Investors, LLC, a Delaware limited liability company, and SVB Financial Group, a Delaware corporation (each a “Holder” and collectively, “Holders”). Capitalized terms used herein but not defined herein shall have the respective meanings ascribed to them in those certain Warrants issued by the Company to PFG and its designees named above dated as of March 22, 2017 (the “PFG Warrants”).
